Report Detail
Global (United States, European Union and China) Cancer Monoclonal Antibodies Market Research Report 2019-2025
- RnM3665289 |
- 13 August, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
In 2019, the market size of Cancer Monoclonal Antibodies is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Cancer Monoclonal Antibodies.
This report studies the global market size of Cancer Monoclonal Antibodies, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Cancer Monoclonal Antibodies sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
...
Market Segment by Product Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Market Segment by Application
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Cancer Monoclonal Antibodies status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Cancer Monoclonal Antibodies manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Cancer Monoclonal Antibodies are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Murine Antibodies
- 1.3.3 Chimeric and Humanised Antibodies
- 1.3.4 Fully Humanized Antibodies
- 1.3.5 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Cancer Monoclonal Antibodies Market Share by Application (2019-2025)
- 1.4.2 Liver
- 1.4.3 Breast
- 1.4.4 Blood
- 1.4.5 Brain
- 1.4.6 Hodgkins and Non-Hodgkins lymphoma
- 1.4.7 Colorectal
- 1.4.8 Leukaemia
- 1.4.9 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Cancer Monoclonal Antibodies Market Size
- 2.1.1 Global Cancer Monoclonal Antibodies Revenue 2014-2025
- 2.1.2 Global Cancer Monoclonal Antibodies Sales 2014-2025
- 2.2 Cancer Monoclonal Antibodies Growth Rate by Regions
- 2.2.1 Global Cancer Monoclonal Antibodies Sales by Regions 2014-2019
- 2.2.2 Global Cancer Monoclonal Antibodies Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Cancer Monoclonal Antibodies Sales by Manufacturers
- 3.1.1 Cancer Monoclonal Antibodies Sales by Manufacturers 2014-2019
- 3.1.2 Cancer Monoclonal Antibodies Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Cancer Monoclonal Antibodies Revenue by Manufacturers (2014-2019)
- 3.2.2 Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
- 3.3 Cancer Monoclonal Antibodies Price by Manufacturers
- 3.4 Key Manufacturers Cancer Monoclonal Antibodies Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Cancer Monoclonal Antibodies Market
- 3.6 Key Manufacturers Cancer Monoclonal Antibodies Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Murine Antibodies Sales and Revenue (2014-2019)
- 4.1.2 Chimeric and Humanised Antibodies Sales and Revenue (2014-2019)
- 4.1.3 Fully Humanized Antibodies Sales and Revenue (2014-2019)
- 4.1.4 Others Sales and Revenue (2014-2019)
- 4.2 Global Cancer Monoclonal Antibodies Sales Market Share by Type
- 4.3 Global Cancer Monoclonal Antibodies Revenue Market Share by Type
- 4.4 Cancer Monoclonal Antibodies Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Cancer Monoclonal Antibodies Sales by Application
6 United States
- 6.1 United States Cancer Monoclonal Antibodies Breakdown Data by Company
- 6.2 United States Cancer Monoclonal Antibodies Breakdown Data by Type
- 6.3 United States Cancer Monoclonal Antibodies Breakdown Data by Application
7 European Union
- 7.1 European Union Cancer Monoclonal Antibodies Breakdown Data by Company
- 7.2 European Union Cancer Monoclonal Antibodies Breakdown Data by Type
- 7.3 European Union Cancer Monoclonal Antibodies Breakdown Data by Application
8 China
- 8.1 China Cancer Monoclonal Antibodies Breakdown Data by Company
- 8.2 China Cancer Monoclonal Antibodies Breakdown Data by Type
- 8.3 China Cancer Monoclonal Antibodies Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Cancer Monoclonal Antibodies Breakdown Data by Company
- 9.2 Rest of World Cancer Monoclonal Antibodies Breakdown Data by Type
- 9.3 Rest of World Cancer Monoclonal Antibodies Breakdown Data by Application
- 9.4 Rest of World Cancer Monoclonal Antibodies Breakdown Data by Countries
- 9.4.1 Rest of World Cancer Monoclonal Antibodies Sales by Countries
- 9.4.2 Rest of World Cancer Monoclonal Antibodies Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 F. Hoffmann-La Roche
- 10.1.1 F. Hoffmann-La Roche Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Cancer Monoclonal Antibodies
- 10.1.4 Cancer Monoclonal Antibodies Product Introduction
- 10.1.5 F. Hoffmann-La Roche Recent Development
- 10.2 Amgen
- 10.2.1 Amgen Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Cancer Monoclonal Antibodies
- 10.2.4 Cancer Monoclonal Antibodies Product Introduction
- 10.2.5 Amgen Recent Development
- 10.3 Bristol-Myers Squibb
- 10.3.1 Bristol-Myers Squibb Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Cancer Monoclonal Antibodies
- 10.3.4 Cancer Monoclonal Antibodies Product Introduction
- 10.3.5 Bristol-Myers Squibb Recent Development
- 10.4 Takeda Pharmaceuticals
- 10.4.1 Takeda Pharmaceuticals Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Cancer Monoclonal Antibodies
- 10.4.4 Cancer Monoclonal Antibodies Product Introduction
- 10.4.5 Takeda Pharmaceuticals Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Cancer Monoclonal Antibodies Sales Channels
- 11.2.2 Cancer Monoclonal Antibodies Distributors
- 11.3 Cancer Monoclonal Antibodies Customers
12 Market Forecast
- 12.1 Global Cancer Monoclonal Antibodies Sales and Revenue Forecast 2019-2025
- 12.2 Global Cancer Monoclonal Antibodies Sales Forecast by Type
- 12.3 Global Cancer Monoclonal Antibodies Sales Forecast by Application
- 12.4 Cancer Monoclonal Antibodies Forecast by Regions
- 12.4.1 Global Cancer Monoclonal Antibodies Sales Forecast by Regions 2019-2025
- 12.4.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on CancerMonoclonalAntibodies. Industry analysis & Market Report on CancerMonoclonalAntibodies is a syndicated market report, published as Global (United States, European Union and China) Cancer Monoclonal Antibodies Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of CancerMonoclonalAntibodies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
